
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser for independent advice.

If you have sold or transferred all your shares in Shenzhen Neptunus Interlong Bio-technique Company Limited, you should at once hand this circular with the accompanying reply slip and form of proxy to the purchaser(s), transferee(s) or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

- (i) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS WHO HAVE SERVED FOR MORE THAN NINE YEARS**
- (ii) PROPOSED DIRECTORS AND SUPERVISORS REMUNERATION PACKAGES OF THE NEW SESSION OF THE BOARD AND THE SUPERVISORY COMMITTEE**
- (iii) CLOSURE OF REGISTER OF MEMBERS**
- AND**
- (iv) NOTICE OF ANNUAL GENERAL MEETING**
-

A notice convening the Annual General Meeting of Shenzhen Neptunus Interlong Bio-technique Company Limited* to be held at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the People's Republic of China (the "PRC") on Wednesday, 21 June 2023 at 10:00 a.m. is set out on pages 22 to 25 of this circular. The relevant form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of GEM (<http://www.hkgem.com>) and the Company (www.interlong.com).

Whether or not you are able to attend the Annual General Meeting in person, please complete and return the accompanying form of proxy in accordance with the instructions printed thereon, in the case of holders of H Shares (as defined below), to the Company's H share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road Hong Kong, and in the case of holders of Domestic Shares (as defined below), to the registered office of the Company at Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the PRC as soon as possible but in any event not less than 24 hours before the time appointed for the Annual General Meeting (i.e. not later than 10:00 a.m. on Tuesday, 20 June 2023). Completion and return of the accompanying form of proxy will not preclude you from attending and voting at the meeting or any adjourned meeting should you so wish and in such event, the instrument appointing a proxy will be deemed to be revoked.

This circular will remain on the GEM website at www.hkgem.com on the "Latest Company Announcements" page for at least 7 days from the date of its posting and in the Company's website at www.interlong.com.

References to time and dates in this circular are to Hong Kong time and dates.

* For identification purpose only

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

RESPONSIBILITY STATEMENT

This circular, for which the directors of the Company (the “**Directors**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement herein or this circular misleading.

CONTENTS

	<i>PAGE</i>	
DEFINITIONS	1	
 LETTER FROM THE BOARD		
1. INTRODUCTION	4	
2. PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS WHO HAVE SERVED FOR MORE THAN NINE YEARS	4	
3. PROPOSED DIRECTORS AND SUPERVISORS REMUNERATION PACKAGES OF THE NEW SESSION OF THE BOARD AND THE SUPERVISORY COMMITTEE	7	
4. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT	8	
5. CLOSURE OF REGISTER OF MEMBERS	9	
6. RECOMMENDATION	9	
 APPENDIX – DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING		10
NOTICE OF ANNUAL GENERAL MEETING	22	

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following respective meanings:

“Annual General Meeting”	the annual general meeting of the Company to be held at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the PRC, on Wednesday, 21 June 2023 at 10:00 a.m., to consider, and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 22 to 25 of this circular, or any adjournment thereof;
“Articles of Association”	the articles of association of the Company currently in force;
“Board”	the board of Directors;
“Company”	深圳市海王英特龍生物技術股份有限公司 (Shenzhen Neptunus Interlong Bio-technique Company Limited*), a joint stock company incorporated in the PRC, whose H shares are listed on GEM;
“Company Law”	the Company Law of the PRC;
“Director(s)”	the director(s) of the Company;
“Domestic Share(s)”	ordinary share(s) of nominal value of RMB0.10 each in the issued share capital of the Company which are subscribed for or credited as paid up in Renminbi;
“GEM”	GEM operated by the Stock Exchange;
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM;
“Group”	the Company and its subsidiaries;
“HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong;
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC;
“H Share(s)”	ordinary share(s) of nominal value of RMB0.10 each in the issued share capital of the Company which are listed and traded on GEM;
“Latest Practicable Date”	15 May 2023, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein;

DEFINITIONS

“Neptunus Bio-engineering”	深圳市海王生物工程股份有限公司 (Shenzhen Neptunus Bio-engineering Company Limited*), a joint stock limited company established under the laws of the PRC with a registered capital of RMB2,762,583,257 whose shares are listed on the Shenzhen Stock Exchange;
“Nomination Committee”	the Company’s nomination committee which was established in accordance with the requirements of the GEM Listing Rules, for the purposes as set out in its terms of reference as amended from time to time;
“PRC”	the People’s Republic of China;
“Remuneration Committee”	the Company’s remuneration committee which was established in accordance with the requirements of the GEM Listing Rules, for the purposes as set out in its terms of reference as amended from time to time;
“RMB”	Renminbi, the lawful currency of the PRC;
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended;
“Share(s)”	the Domestic Shares and the H Shares;
“Shareholder(s)”	shareholder(s) (both holders of Domestic Shares and H Shares) of the Company;
“Shenzhen Neptunus”	深圳海王集团股份有限公司 (Shenzhen Neptunus Group Company Limited*), a joint stock limited company incorporated in the PRC and the controlling shareholder of Neptunus Bio-engineering;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited; and
“%”	per cent.

* For identification purpose only

LETTER FROM THE BOARD



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

Executive Directors:
Mr. Zhang Feng (*Chairman*)
Mr. Huang Jian Bo

Non-executive Directors:
Mr. Zhang Yi Fei
Ms. Yu Lin
Mr. Shen Da Kai
Mr. Jin Rui

Independent Non-executive Directors:
Mr. Yick Wing Fat, Simon
Mr. Poon Ka Yeung
Mr. Zhang Jian Zhou

Registered Office:
Suite 1702,
Neptunus Yinhe Technology Mansion,
1 Keji Middle 3rd Road,
Maling Community,
Yuehai Sub-district,
Nanshan District, Shenzhen, the PRC

Principal Place of Business in Hong Kong:
18th Floor
United Centre
95 Queensway
Admiralty
Hong Kong

Shenzhen, the PRC, 19 May 2023

To the Shareholders

Dear Sir or Madam,

- (i) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS WHO HAVE SERVED FOR MORE THAN NINE YEARS**
- (ii) PROPOSED DIRECTORS AND SUPERVISORS REMUNERATION PACKAGES OF THE NEW SESSION OF THE BOARD AND THE SUPERVISORY COMMITTEE**
- (iii) CLOSURE OF REGISTER OF MEMBERS**
- AND**
- (iv) NOTICE OF ANNUAL GENERAL MEETING**

* For identification purpose only

LETTER FROM THE BOARD

1. INTRODUCTION

The purpose of this circular is to give you notice of the Annual General Meeting and to provide you with information regarding certain resolutions to be proposed at the Annual General Meeting to enable you to make an informed decision on whether to vote for or against those resolutions at the Annual General Meeting.

2. PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPERVISORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS WHO HAVE SERVED FOR MORE THAN NINE YEARS

(1) Proposed re-election and appointment of Directors and continuous appointment of independent non-executive Directors who have served for more than nine years

As at the Latest Practicable Date, the Board comprised of 9 members, including Mr. Zhang Feng and Mr. Huang Jian Bo as executive Directors, Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Jin Rui as non-executive Directors, and Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou as independent non-executive Directors.

According to the article 114 of the Articles of Association, the term of office of the Directors is for three years, and the term of office of a Director who is appointed to fill up a vacant position on the Board shall be the remaining term of the Director who is out-of-office, and all Directors shall be eligible for re-election upon the expiration of the term of office. Therefore, the term of office of each of the Directors of the current session of the Board will expire on 24 June 2023, among which, i) the term of office of Mr. Zhang Yi Fei commenced from 18 June 2021; ii) the term of office of Mr. Jin Rui commenced from 24 June 2022; and iii) the term of office of the rest of the Directors commenced from 25 June 2020.

Due to work arrangement, Mr. Shen Da Kai has notified the Board that he will retire from his office as a non-executive Director and will not seek for re-election. Mr. Shen has confirmed that he have no disagreement with the Board and the Company and there is no other matter in relation to his retirement that needs to be brought to the attention to the Shareholders.

The Board hereby announces that Mr. Zhang Feng and Mr. Huang Jian Bo were nominated as candidates for re-election as executive Directors for the new session of the Board, Mr. Zhang Yi Fei, Ms. Yu Lin and Mr. Jin Rui were nominated as candidates for re-election as non-executive Directors for the new session of the Board, and Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou were nominated as candidates for re-election as independent non-executive Directors for the new session of the Board. At the Annual General Meeting, all Directors are eligible and will offer themselves for re-election, and resolutions will be proposed to elect each of them for a term of 3 years.

LETTER FROM THE BOARD

In addition, Mr. Zhang Xiao Guang was nominated as a candidate for election as executive Director for the new session of the Board.

The term of office of the elected and re-elected Directors will be for a period of 3 years which is proposed to commence on 25 June 2023.

According to code provision B.2.3 of the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules, if an independent non-executive director serves more than nine years, any further appointment of such independent non-executive director should be subject to a separate resolution to be approved by the shareholders.

Mr. Yick Wing Fat, Simon has served as an independent non-executive Director for more than 9 years. The Company has received from Mr. Yick a confirmation of independence according to Rule 5.09 of the GEM Listing Rules. In addition, Mr. Yick did not involve in the day-to-day management of the Company, did not have any family ties nor other relationship with other Directors or senior management or substantial shareholder or controlling shareholder of the Company, and the Company is not aware of any circumstance which would interfere with the exercise of his professional judgment. The Nomination Committee of the Company also noted the positive contributions from Mr. Yick to the development of the Company's strategy and policies through independent and constructive contributions supported by his skills, expertise and qualifications and from his participations at meetings. Taking into consideration of his independent scope of work in the past years and the above factors, the Board and the Nomination Committee consider Mr. Yick to be independent under the GEM Listing Rules despite the fact that he has served the Company for more than nine years. The Board and the Nomination Committee believe that Mr. Yick's continued tenure brings considerable stability to the Board and the Board has benefited greatly from the presence of Mr. Yick who has over time gained valuable insight into the Group. Separate resolution will be proposed for his re-election at the Annual General Meeting.

Mr. Poon Ka Yeung has served as an independent non-executive Director for more than 9 years. The Company has received from Mr. Poon a confirmation of independence according to Rule 5.09 of the GEM Listing Rules. In addition, Mr. Poon did not involve in the day-to-day management of the Company, did not have any family ties nor other relationship with other Directors or senior management or substantial shareholder or controlling shareholder of the Company and the Company is not aware of any circumstance which would interfere with the exercise of his professional judgment. The Nomination Committee of the Company also noted the positive contributions from Mr. Poon to the development of the Company's strategy and policies through independent, constructive and informed contributions supported by his skills, expertise and qualifications and from his participations at meetings. Taking into consideration of his independent scope of work in the past years and the above factors, the Board and the Nomination Committee consider Mr. Poon to be independent under the GEM Listing Rules despite the fact that he has served the Company for more than nine years. The Board and the Nomination Committee believe that Mr. Poon's continued tenure brings considerable stability to the Board and the Board has benefited

LETTER FROM THE BOARD

greatly from the presence of Mr. Poon who has over time gained valuable insight into the Group. Separate resolution will be proposed for his re-election at the Annual General Meeting.

The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution of the retiring Directors with reference to the nomination principles and criteria set out in the Company's Board Diversity Policy and Director Nomination Policy and the Company's corporate strategy, and the independence of all independent non-executive Directors. The Nomination Committee has recommended to the Board on the re-election of all the retiring Directors including the aforesaid independent non-executive Directors who are due to retire at the Annual General Meeting.

Accordingly, the proposed new session of the Board will consist of nine Directors, including three executive Directors, three non-executive Directors and three independent non-executive Directors.

The biographical details of the candidates proposed to be re-elected and appointed as Directors at the Annual General Meeting are set out in the Appendix to this circular.

(2) Proposed re-election of Supervisors

As at the Latest Practicable Date, the Supervisory Committee comprised of three members, including Mr. Xiong Chu Xiong, Mr. Jin Ge and the employee representative Supervisor Ms. Cao Yang.

Pursuant to the article 148 of the Articles of Association, independent Supervisors are to be elected at the general meeting and the employee representative Supervisors are to be elected through democratic election by the Company's staff. The results shall be notified to the Shareholders at the general meeting.

According to the article 147 of the Articles of Association, the term of office of the Supervisors is for three years and shall be eligible for re-election. The term of office of each of the Supervisors of current session of the Supervisory Committee commenced on 25 June 2020 and will expire on 24 June 2023.

The Supervisory Committee proposes to re-elect Mr. Xiong Chu Xiong and Mr. Jin Ge as Supervisors of the new session of the Supervisory Committee. They, together with an employee representative Supervisor who will be elected by the Company's employees, will form the new session of the Supervisory Committee. At the Annual General Meeting, Mr. Xiong Chu Xiong and Mr. Jin Ge are eligible and will offer themselves for re-election as Supervisors for the new session of the Supervisory Committee and resolutions will be proposed to elect them for a term of 3 years. The term of office of the re-elected Supervisors will be for a period of 3 years which is proposed to commence on 25 June 2023.

LETTER FROM THE BOARD

The biographical details of the candidates proposed to be re-elected as Supervisors at the Annual General Meeting are set out in the Appendix to this circular.

3. PROPOSED DIRECTORS AND SUPERVISORS REMUNERATION PACKAGES OF THE NEW SESSION OF THE BOARD AND THE SUPERVISORY COMMITTEE

Below is the proposal on the proposed remuneration packages of the Directors and Supervisors of the new session of the Board and the Supervisory Committee to be presented to the Shareholders for approval at the Annual General Meeting:

(1) Directors remuneration package of the new session of the Board

Name	Position	Directors' Fees (for a term of 3 years commencing from 25 June 2023)
Zhang Feng	executive Director	RMB100,000 per annum
Huang Jian Bo	executive Director	RMB100,000 per annum
Zhang Xiao Guang	executive Director	RMB100,000 per annum
Zhang Yi Fei	non-executive Director	RMB100,000 per annum
Yu Lin	non-executive Director	RMB100,000 per annum
Jin Rui	non-executive Director	RMB100,000 per annum
Yick Wing Fat, Simon	independent non-executive Director	RMB212,000 per annum
Poon Ka Yeung	independent non-executive Director	RMB106,000 per annum
Zhang Jian Zhou	independent non-executive Director	RMB100,000 per annum

Note:

- i) The Directors' fees aforementioned are tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax; and
- ii) Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by the Directors for the provision of Director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

(2) Supervisors remuneration package of the new Supervisory Committee

- (a) Each of the Supervisors elected by the Shareholders will be entitled to a Supervisor's remuneration of RMB30,000 per annum, for a term of 3 years commencing from 25 June 2023; and
- (b) The employee representative Supervisor will be entitled to a Supervisor's subsidy of RMB20,000 per annum, for a term of 3 years commencing from 25 June 2023.

LETTER FROM THE BOARD

Note:

- i) The Supervisors' remuneration and subsidy aforementioned are tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax; and
- ii) Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by the Supervisors for the provision of Supervisor's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

4. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 22 to 25 of this circular.

Pursuant to the GEM Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under the GEM Listing Rules.

The relevant form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the website of GEM (www.hkgem.com) and the website of the Company (www.interlong.com). Whether or not you intend to attend the Annual General Meeting in person, you are requested to complete, sign and return (i) the enclosed form of proxy in accordance with the instructions printed thereon as soon as possible but in any event not less than 24 hours before the time appointed for the Annual General Meeting (i.e. not later than 10:00 a.m. on Tuesday, 20 June 2023). Completion and return of the form of proxy will not preclude you from attending the Annual General Meeting and voting in person if you so wish in which event the relevant form(s) of proxy shall be deemed revoked.

LETTER FROM THE BOARD

5. CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Friday, 16 June 2023 to Wednesday, 21 June 2023, both days inclusive, during which no transfer of Shares will be effected. As regards holders of H Shares, in order to qualify for attending the Meeting, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company's H share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on Thursday, 15 June 2023.

6. RECOMMENDATION

The Directors consider that all resolutions proposed for consideration and approval by the Shareholders at the Annual General Meeting are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

Yours faithfully,
By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

* *For identification purpose only*

APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING

The following are details of the existing Directors and Supervisors who will retire and being eligible, offer themselves for re-election and details of the proposed Director to be appointed at the Annual General Meeting.

(1) EXECUTIVE DIRECTORS

Mr. Zhang Feng (張鋒), aged 50, has been appointed as the chairman of the Board and compliance officer of the Company since June 2011, and was appointed as the authorized representative of the Company on 8 February 2021. He obtained an MBA degree from University of Technology, Sydney. Mr. Zhang studied in Göteborg University, Sweden. He was a member of the 13th National Committee of Chinese People's Political Conference, a committee member of the 10th and 11th and a standing committee member of the 12th Jilin Municipal Provincial Committee of the Chinese People's Political Consultative Conference, the deputy chairman of the 10th, 11th and 12th sessions of Jilin Youth Federation (吉林省青年聯合會), the president of the 8th session of and the honorary president of the 9th session of council of Jilin Province Youth Entrepreneurs Association (吉林省青年企業家協會) and the part-time deputy chairman of the 11th Jilin Federation of Industry and Commerce (吉林省工商聯). Mr. Zhang was the general manager of Shenzhen Neptunus Pharmaceutical Co., Ltd. ("**Neptunus Pharmaceutical**") and Shenzhen Neptunus Tongai Pharmaceutical Manufacturing Company Ltd. and the deputy general manager and chief branding and marketing officer of Neptunus Bio-engineering. He is currently the deputy chairman and non-independent director of the 9th session of the board of directors and president of Neptunus Bio-engineering, the director of Shenzhen Neptunus, Shenzhen Quanyaowang Technology Company Limited (深圳市全藥網科技有限公司) and Ascendent BioTechnology Company Limited, the chairman of the board of directors of Shenzhen Neptunus Changjian Pharmaceutical Co., Ltd. ("**Neptunus Changjian**"), the chairman of the board of directors and the legal representative of Neptunus Pharmaceutical, the director of Fuzhou Neptunus Fuyao Pharmaceutical Co., Ltd. ("**Neptunus Fuyao**") and Fuzhou Neptunus Jinxiang Chinese Pharmaceutical Company Limited ("**Neptunus Jinxiang**") and the chairman of the board of directors and director of several other companies.

So far as the Directors are aware as at the Latest Practicable Date, Mr. Zhang was interested within the meaning of Part XV of the SFO in 1,331,093 shares of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company. Save as disclosed above, Mr. Zhang does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company. Save as disclosed above, Mr. Zhang did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Zhang will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Zhang and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Zhang the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Zhang for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Zhang that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Mr. Huang Jian Bo (黃劍波), aged 46, has been appointed as an executive director of the Board, joint company secretary and authorized representative of the Company since June 2020, vice general manager of the Company since 24 April 2020 and the Board secretary and the financial controller of the Company since 13 May 2020. Mr. Huang graduated from Hunan University with a bachelor's degree in economics and majoring in finance and is a member of the Chinese Institute of Certified Public Accountants. He has extensive experience in listing operations, financial management and investment management. Mr. Huang has worked in the Company during the period from February 2003 to April 2016, and served as the chief financial officer, joint company secretary, Board secretary and authorised representative of the Company. He was the financial controller of each of Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd. (安徽九華華源藥業有限公司) and Shenzhen Ainengsen Technology Co., Ltd. (深圳愛能森科技有限公司). Mr. Huang is currently a director of Neptunus Changjian and the chairman of supervisory committee of Beijing Neptunus Zhongxin Pharmaceutical Co., Ltd. ("**Neptunus Zhongxin**").

Save as disclosed above, Mr. Huang does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Huang did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Huang will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Huang and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Huang the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Huang for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Huang that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Mr. Zhang Xiao Guang (張曉光), aged 57, graduated from China FAW Group Workers College (中國第一汽車集團職工大學), majoring in mechanical and electrical automation. Mr. Zhang has been working in the pharmaceutical industry for over 20 years and officially joined the Neptunus Group in 2009. He has served as the sales manager, the provincial manager of Shanxi and Jilin provinces, the sales director of the north China region, and the deputy national sales supervisor and deputy national sales general manager of Neptunus Changjian. Mr. Zhang is currently the general manager of Neptunus Changjian.

Mr. Zhang has extensive experience in sales management and has won multiple awards in the industry, including the Outstanding Management Team Award and Excellent Manager Award of the OTC Sales Department of Neptunus Changjian.

Save as disclosed above, Mr. Zhang does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Zhang did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his appointment at the Annual General Meeting, Mr. Zhang will serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A service agreement will also be entered into between Mr. Zhang and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the service agreement, the Company will pay Mr. Zhang the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Zhang for the provision of director's service to the Company or due to the execution of work relevant to matters for the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Zhang that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

(2) NON-EXECUTIVE DIRECTORS

Mr. Zhang Yi Fei (張翼飛), aged 50, has been appointed as a non-executive director of the Company since 1 March 2021. Mr. Zhang obtained his bachelor's degree in Technical Economics in 1996 and a master's degree in Management Science and Engineering in 2015 from the School of Management, Harbin Institute of Technology. He previously served various roles, including secretary of the president office of Shenzhen Neptunus, sales manager of Sanya branch, regional sales manager of Heilongjiang province, manager of the northeast region, nation-wide commercial director, assistant general manager and operations director, director and the deputy general manager of Neptunus Bio-engineering. He had also acted as the general manager of Zhejiang Huafang Life Technology Co., Ltd. (浙江華方生命科技有限公司). Mr. Zhang is currently the executive vice president and non-independent director of Neptunus Bio-engineering, the legal representative, chairman of the board of directors and general manager of Jilin Neptunus Yinhe Pharmaceutical Investment Co., Ltd., the chairman of the board of directors of Neptunus Fuyao and Neptunus Zhongxin, and a director of several other companies.

Save as disclosed above, Mr. Zhang does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Zhang did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Zhang will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Zhang and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Zhang the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Zhang for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Zhang that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Ms. Yu Lin (于琳), aged 65, has been appointed as a non-executive director of the Company since February 2005. Ms. Yu graduated from Sun Yat-sen University of the PRC, and has more than 30 years of experience in biochemical and pharmaceutical industries in the PRC. Ms. Yu was the director and vice-president of Neptunus Bio-engineering and was responsible for the research and development of new products. Currently she is a director of Shenzhen Neptunus Pharmaceutical Technology Research Company Limited, Neptunus Pharmaceutical and Neptunus Zhongxin.

So far as the Directors are aware as at the Latest Practicable Date, Ms. Yu was interested within the meaning of Part XV of the SFO in 900,000 shares of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company. Save as disclosed above, Ms. Yu does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company. Save as disclosed above, Ms. Yu did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after her re-election at the Annual General Meeting, Ms. Yu will continue to serve on the Board until she resigns or is removed and she will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Ms. Yu and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Ms. Yu the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to her duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Ms. Yu for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Ms. Yu that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Mr. Jin Rui (金銳), aged 38, has been appointed as a non-executive director of the Company since 13 May 2022. Mr. Jin obtained a bachelor's degree from Nanjing University in 2007 and a master's degree from Zhejiang University in 2013. Mr. Jin previously served various roles in the management level in a number of companies, including the assistant president of Holley Group Co., Ltd., the vice president of Holley Pharmaceutical Group Co., Ltd, and a director of Zhejiang Wazam New Materials Co., Ltd. and Anhui Neptunus Pharmaceutical Group Co., Ltd. He is currently the vice president and non-independent director of Neptunus Bio-engineering and a director of Neptunus Fuyao, Neptunus Jinxiang and several other companies.

Save as disclosed above, Mr. Jin does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Jin did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Jin will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Jin and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Jin the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Jin for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Jin that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

(3) INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Yick Wing Fat, Simon (易永發), aged 65, has been appointed as an independent non-executive director of the Company since August 2005. Mr. Yick holds a bachelor's degree in business administration, majoring in accounting, from the Chinese University of Hong Kong. He is a fellow member of both the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants in England. Mr. Yick has more than 30 years of experience in auditing, direct investment, investment banking and corporate advisory services. From August 2015 to August 2020, Mr. Yick was an independent non-executive director, the convener of the nomination committee and a member of the strategy committee of Chengdu Xingrong Environment Co., Ltd. (the shares of which are listed on the Shenzhen Stock Exchange), and Mr. Yick was an independent non-executive director, the chairman of the remuneration and nomination committee and a member of the audit and compliance committee of Nexteer Automotive Group Limited (the shares of which are listed on the Main Board of the Stock Exchange) from August 2017 to June 2020. In addition, Mr. Yick is an independent non-executive director and chairman of the audit committee of Shanghai International Shanghai Growth Investment Limited, China Shuifa Singyes Energy Holdings Limited (formerly known as "China Singyes Solar Technologies Holdings Limited") and Meta Media Holdings Limited (formerly known as "Modern Media Holdings Limited") (the shares of these three companies are listed on the Main Board of the Stock Exchange).

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Save as disclosed above, Mr. Yick does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Yick did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

Upon the approval and after his re-election at the Annual General Meeting, Mr. Yick will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Yick and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Yick the director's fee of RMB212,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Yick for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Yick that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to(v) of the GEM Listing Rules.

Mr. Poon Ka Yeung (潘嘉陽), aged 56, has been appointed as an independent non-executive director of the Company since August 2005. Mr. Poon obtained his bachelor's degree in mathematics with minor in economics and marketing from the Chinese University of Hong Kong in 1989 and was further admitted to the MBA degree by the University of Hull, United Kingdom, in 1996. Mr. Poon has been appointed as an Honorary Institute Fellow of the Asia-Pacific Institute of Business of the Chinese University of Hong Kong since April 2002. He has been teaching marketing-related subjects for the master's degree in science program, MBA program and Global Executive MBA program (OneMBA) of the Chinese University of Hong Kong. Since June 2008, he has been appointed as visiting Adjunct Associate Professor in the Department of Marketing of the Chinese University of Hong Kong. In addition, Mr. Poon has been appointed as an independent non-executive director and a member of audit, remuneration and nomination committees of Great Eagle Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange) since March 2016. On 22 December 2021, Mr. Poon was redesignated to an executive director of Great Eagle Holdings Limited, presiding over the investment in innovative technology.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Save as disclosed above, Mr. Poon does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Poon did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

Upon the approval and after his re-election at the Annual General Meeting, Mr. Poon will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Poon and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Poon the director's fee of RMB106,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Poon for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Poon that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Mr. Zhang Jian Zhou (章劍舟), aged 53, has been appointed as an independent non-executive director of the Company since January 2016. Mr. Zhang graduated from China Youth University of Political Studies with a B.A. degree in 1990, from Beijing Foreign Studies University with a LL.B degree in 1992, and from Boston University with a LL.M degree in 2002. He had been an assistant professor of International Trade Law at Guangdong University of Technology from 1992 to 1993. Mr. Zhang has been in private practice since 1993 when he was qualified to practice law in the PRC. He is now a partner of Beijing Anjie (Shenzhen) Law Firm.

Save as disclosed above, Mr. Zhang does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Zhang did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Zhang will continue to serve on the Board until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Zhang and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Zhang the director's fee of RMB100,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax), such amount is determined by the Board with reference to his duties, responsibilities and the performance and results of the Company, and shall be reviewed by the remuneration committee from time to time. Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Zhang for the provision of director's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Zhang that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

(4) SUPERVISORS

Mr. Xiong Chu Xiong (熊楚熊), aged 67, has been appointed as a supervisor of the Company since June 2008. Mr. Xiong obtained a doctorate degree in accountancy from Xiamen University in 1992. Mr. Xiong was an accounting professor of Shenzhen University and now he is retired. Mr. Xiong was an independent director of Neptunus Bio-engineering, China National Accord Medicines Corporation Ltd. (國藥集團一致藥業股份有限公司), Shenzhen Wongtee International Enterprise Co., Ltd. (深圳市皇庭國際企業股份有限公司), Shahe Industrial Co., Ltd. (沙河實業股份有限公司) and Shenzhen Laibao Hi-Tech Co., Ltd. (深圳萊寶高科股份有限公司), the shares of which are listed on Shenzhen Stock Exchange. Mr. Xiong is currently a director of UBTECH Robotics Corp Ltd.

Save as disclosed above, Mr. Xiong does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Xiong did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Xiong will continue to serve as a Supervisor until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Xiong and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Xiong the supervisor's remuneration of RMB30,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax). Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Xiong for the provision of supervisor's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Xiong that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Mr. Jin Ge (金戈), aged 54, has been appointed as a supervisor of the Company since 25 June 2020. Mr. Jin graduated from Macau University of Science and Technology with a master of business administration degree. He has been engaged in the pharmaceutical and related industries for 25 years, specialising in finance, auditing and financial work. He is familiar with the pharmaceutical market in mainland China, and has extensive experience in financial management and auditing in the pharmaceutical industry. Since 2009, he has been an external tutor at the School of Business of Sun Yat-sen University, serving as a thesis instructor for the degrees of master of business administration, master of professional accounting, etc.. He joined Neptunus Group in 1994, and served as accountant, finance supervisor and deputy finance manager of Neptunus Pharmaceutical, finance director of marketing centre of Neptunus Bio-engineering, and finance director of Shenzhen Neptunus Healthy Technology Development Co., Ltd. He was a director and vice president of Shenzhen Kind Care Group Co., Ltd. (深圳市一德集團有限公司), being in charge of group finance, auditing and investment and financing work, the vice chairman of Shenzhen Xingye Financing Guarantee Co., Ltd. (深圳市興業融資擔保有限公司), the director and vice president of Shenzhen Qianhai Kind Care Holdings Co., Ltd. (深圳市前海一德控股有限公司), and the assistant to chairman of Shenzhen Neptunus. He is currently the vice-president of Neptunus Bio-engineering and a supervisor of Neptunus Fuyao, Neptunus Jinxiang and several other companies.

Save as disclosed above, Mr. Jin does not hold any other positions with the Company and any other members of the Group and does not have any relationship with any Directors, Supervisors, senior management, substantial or controlling shareholders of the Company, nor does he have any interests in the securities of the Company or its associated corporation within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Jin did not hold any directorship in other listed public companies of which their securities are listed on any securities market in Hong Kong or overseas in the past three years.

**APPENDIX DETAILS OF THE DIRECTORS AND SUPERVISORS PROPOSED TO BE
RE-ELECTED AND APPOINTED AT THE ANNUAL GENERAL MEETING**

Upon the approval and after his re-election at the Annual General Meeting, Mr. Jin will continue to serve as a Supervisor until he resigns or is removed and he will be subject to retirement and re-election at the annual general meeting in accordance with the Articles of Association. A new service agreement will also be entered into between Mr. Jin and the Company with a term of office of 3 years commencing from 25 June 2023. Pursuant to the new service agreement, the Company will pay Mr. Jin the supervisor's remuneration of RMB30,000 per annum (which is tax inclusive and to be paid on a monthly basis with the Company being responsible for withholding personal income tax). Within the permitted scope regulated by relevant laws, regulations and policies of the PRC, any reasonable and necessary expenses (including but not limited to travel expenses) paid by Mr. Jin for the provision of supervisor's service to the Company or due to the execution of work relevant to the Company's operation will be borne by the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Mr. Jin that need to be brought to the attention of the Shareholders, nor is there any information required to be disclosed under Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

NOTICE OF ANNUAL GENERAL MEETING



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting (the “**Meeting**”) of 深圳市海王英特龍生物技術股份有限公司 (Shenzhen Neptunus Interlong Bio-technique Company Limited*) (the “**Company**”) will be held at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the People’s Republic of China (the “**PRC**”) on Wednesday, 21 June 2023 at 10:00 a.m. for the purpose of considering and, if thought fit, passing, with or without modifications, the resolutions set out below. Unless the context otherwise requires, the terms defined in the circular of the Company dated 19 May 2023 (the “**Circular**”) shall have the same meaning herein.

ORDINARY RESOLUTIONS

1. To consider and approve the audited consolidated financial statements of the Company and its subsidiaries for the year ended 31 December 2022.
2. To consider and approve the reports of the board (the “**Board**”) of directors (the “**Directors**”) of the Company and the auditors for the year ended 31 December 2022.
3. To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2022.
4. To consider and approve the re-appointment of Grant Thornton Hong Kong Limited as the auditors of the Company to hold office until the conclusion of the next annual general meeting and to authorise the Board to fix their remuneration.
5. To consider and approve the annual budget and final accounts of the Company.
6. (a) To consider and approve the re-election of Mr. Zhang Feng (張鋒) as executive Director for a term of 3 years with effect from 25 June 2023;
(b) To consider and approve the re-election of Mr. Huang Jian Bo (黃劍波) as executive Director for a term of 3 years with effect from 25 June 2023;

* For identification purpose only

NOTICE OF ANNUAL GENERAL MEETING

- (c) To consider and approve the appointment of Mr. Zhang Xiao Guang (張曉光) as executive Director for a term of 3 years with effect from 25 June 2023;
 - (d) To consider and approve the re-election of Mr. Zhang Yi Fei (張翼飛) as non-executive Director for a term of 3 years with effect from 25 June 2023;
 - (e) To consider and approve the re-election of Ms. Yu Lin (于琳) as non-executive Director for a term of 3 years with effect from 25 June 2023;
 - (f) To consider and approve the re-election of Mr. Jin Rui (金銳), as non-executive Director for a term of 3 years with effect from 25 June 2023;
 - (g) To consider and approve the re-election of Mr. Yick Wing Fat, Simon (易永發), who has served the Company for more than 9 years, as independent non-executive Director, for a term of 3 years with effect from 25 June 2023;
 - (h) To consider and approve the re-election of Mr. Poon Ka Yeung (潘嘉陽), who has served the Company for more than 9 years as independent non-executive Director, for a term of 3 years with effect from 25 June 2023; and
 - (i) To consider and approve the re-election of Mr. Zhang Jian Zhou (章劍舟) as independent non-executive Director for a term of 3 years with effect from 25 June 2023.
7. (a) To consider and approve the re-election of Mr. Xiong Chu Xiong (熊楚熊) as Supervisor for a term of 3 years with effect from 25 June 2023; and
- (b) To consider and approve the re-election of Mr. Jin Ge (金戈) as Supervisor for a term of 3 years with effect from 25 June 2023.
8. To consider and approve the Directors and Supervisors remuneration packages of the new session of the Board and the Supervisory Committee and details of which are set out in the Circular.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 19 May 2023

* For identification purpose only

NOTICE OF ANNUAL GENERAL MEETING

Registered Office:
Suite 1702
Neptunus Yinhe Technology Mansion
1 Keji Middle 3rd Road
Maling Community
Yuehai Sub-district
Nanshan District, Shenzhen
The PRC

Place of Business in Hong Kong:
18th Floor
United Centre
95 Queensway
Admiralty
Hong Kong

Notes:

1. A shareholder of the Company (the “**Shareholder**”) entitled to attend and vote at the Meeting is entitled to appoint one or more proxies to attend and vote instead of him. A proxy need not be a Shareholder. In the case of joint holders of shares of the Company (the “**Shares**”), any one of such joint holders may sign the form of proxy. However, if more than one of such joint holders are present at the Meeting, whether personally or by proxy, that one of the joint Shareholders so present whose name stands first in the register of Shareholders in respect of such Shares shall alone be entitled to vote in respect thereof.
2. In order to be valid, the form of proxy together with a power of attorney or other authority (if any) under which it is signed or the notarised copy of such power of attorney or authority must be lodged not less than 24 hours before the day appointed for the Meeting (i.e. not later than 10:00 a.m. on Tuesday, 20 June 2023), in the case of holders of H shares of the Company (the “**H Shares**”), with the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited (the “**Company’s H Share Registrar**”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in the case of holders of domestic shares of the Company (the “**Domestic Shares**”), to the Company’s registered office at Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, the PRC.
3. The Shareholders or their proxies will be required to produce proof of their identities (and a copy of the form of proxy in case of proxies) when attending the Meeting.
4. To ascertain the Shareholders’ entitlement to attend and vote at the Meeting, the register of Shareholders will be closed from Friday, 16 June 2023 to Wednesday, 21 June 2023, both days inclusive, during which no transfer of Shares will be effected. As regards holders of H Shares, in order to qualify for attending the Meeting, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H Share Registrar, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, 15 June 2023.
5. The Meeting is expected to last for no more than a day. The Shareholders or their proxies attending the Meeting shall bear their own traveling, accommodation and meal expenses.
6. Voting at the Meeting will be conducted by way of poll.
7. For any enquiries about this notice, please contact the contact person of the general meetings, Mr. Huang Jian Bo, at +86 755 2640 1275.
8. References to time and dates in this notice are to Hong Kong time and dates.

NOTICE OF ANNUAL GENERAL MEETING

As at the date of this notice, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this notice is accurate and complete in all material aspects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this notice or this notice misleading.

This notice will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.